human cancers, which functions as a driver to trigger cancer pathogenesis. In current study, we identified a new catalogue of mutations in RAF and MEK with variable deletions ... mutants with Ã?²3-Ã?±C loop deletions…
Many somatic mutations have been detected in GI cancers, leading to the identification of some key drivers of disease progression, but the involvement of large genomic rearrangements has often been
available bioinformatics databases to identify the driver genes which are dysregulated in non-small cell lung cancer (NSCLC). Also, we identified the mutations in the form of single nucleotide polymorphisms
therefore very important for physicians to be aware of this tendency, its drivers, and the evidence-based data. METHODS We looked at our data from Mediclinic cancer comprehensive center ... risk reducing mastectomy…
frequency. To address this, we have taken an integrative approach to identify driver alterations that can be exploited as therapeutic targets, by i) identifying alterations at higher frequency in rare ... selectively…
share common genes. We mapped their genes onto the network, the common drivers of these two diseases were revealed through two-way RWR analysis. Another example is that the lung ... levels but how the different level…
oncogene KRAS, and inactivating mutations in the tumor suppressor genes CDKN2A, TP53, and SMAD4. Lastly, we describe a new potential PDAC driver gene which we found in 25% of UCOGC
abnormalities such as BRCA gene mutations which can be tested on the cell samples prepared for HPV assays. The cytopathologists are in the drivers’ seat in implementing Sanger sequencing
PDAC) is known as cancer with very poor prognosis. KRAS oncogene is a major driver of PDAC tumorigenesis but its role as prognostic or predictive factor is not clear ... were examined in 45 patients with histologically…
EGFR TKIs usually develop resistance in one year. Mechanisms involving the resistance include T790M mutation, MET amplification, PTEN loss, among others. About 3-8% of lung adenocarcinomas show ALK arrangement…
cases with late dissemination in which the metastatic tumor mostly acquires the same mutational process active in primary tumor and parallel metastatic progression, with early dissemination in the remaining…
cases with late dissemination in which the metastatic tumor mostly acquires the same mutational process active in primary tumor and parallel metastatic progression, with early dissemination in the remaining…
mutated cell that has become dysfunctional and multiplies out of control (the somatic mutation model) is much less consistent with extant data than the context dependent model. The latter focuses ... interactions…
EGFR T790M resistance mutation, which was also detected via a liquid biopsy. Conclusion: Liquid biopsy analyses of ctDNA and CTCs can complement tumor testing, identifying potential drivers of a patient
major driver of prostate cancer initiation and progression. FOXA1, a transcription factor of the FKHD family, was recently found to be among most frequently mutated genes in both localized prostate
Most of the cancers harbor molecular alterations in their genomes. These mutations have not yet been comprehensively explored in the colon cancer. TTYH2, a human homologue of the Drosophila melanogaster ... revealed the…
fact, the mutation of the population lifestyle is effective, which is to say in initial a farmer-breeders may become a breeders, otherwise a rickshaw driver, a security and guard
rearrangements, point mutations, frameshift insertions, amplifications, imprinting, and epigenetic changes implicated in cancer. Microarrays and gene chip analysis, however, are beginning to unveil some key genomic…
genetic and molecular levels. Therefore, we investigated a number of tumor suppressor genes commonly mutated in sporadic breast cancer.In this case-control study, we examined 37 single nucleotide polymorphisms (SNPs…
driver genes in these cases. We also were able to track the antineoplastic response in these groups of patients by monitoring their tumor circulating DNA mutated allele fractions and propose
other transcription factors are disrupted in cancer. Steroid hormone nuclear receptors are oncogenic drivers in breast and prostate cancer and blockade of signaling is a major therapeutic goal. By contrast ... liver and…
drivers through the G1/S transition point. Among the differentially expressed proteins, a rich network of ~200 proteins emerged with biomarker or drug-target potential. The impact of point mutations
that differences in population-level exposure to environmental modifiable risk factors are a key driver of recorded cancer incidence. Several studies have demonstrated the carcinogenic potential of aristolochic acids…
conventional morphological classifications. (2) A significant portion of solid tumors depend on oncogenic driver lesions, which provide molecular targets for prediction of effective and selective therapies. (3) Genomic…
thymidine analogue nucleoside reverse transcriptase (NRTIs) inhibitors account for development of Thymidine Associated Mutations (TAMs) as acquired drug resistance. Late diagnosis of anti-retroviral (ART) failure, use…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.